113 -2 (30/3) 2020 — Mirakhmedova S.S., — ESTIMATION OF EFFECTIVENESS OF TREATMENT OF BREAST CANCER PATIENTS FROM THREE NEGATIVE RECEPTOR STATUS

ESTIMATION OF EFFECTIVENESS OF TREATMENT OF BREAST CANCER PATIENTS FROM THREE
NEGATIVE RECEPTOR STATUS

Mirakhmedova S.S.,- Bukhara State Medical Institute named after Abu Ali Ibn Sina 200101, Uzbekistan, Bukhara city, 1 Navai Avenue.

Resume,

The aim of the study effectiveness of various treatment methods in patients with breast cancer with triple negative receptor status.

Materials and methods: patients with TNBC who participated in the study were characterized by the following symptoms: age 37 ± 8.5 years, the third degree of histopathological differentiation of the tumor, invasive cancer of a nonspecific type as a variant of the morphological structure. Of the total number of examined patients, the following risk factors were identified: 14 (46.67%) had breast cancer in the family, 5 (16.6%) received oral contraceptives, and early menstruation before 12 years was detected in 3 (10%), benign breast hyperplastic processes were detected in 8 (26.6%). (p <0.05)

Key words: breast cancer, neoaduvant chemotherapy, triple negative breast cancer, surgical treatment.

First page

433

Last page

435

For citation: Mirakhmedova S.S., Estimation of effectiveness of treatment of breast cancer patients from three negative receptor status//New Day in Medicine 2(30)2020 433-435 https://cutt.ly/3vIAXEb

List of References

1. Семиглазов В., и др. Биологическое обоснование планирова­ния лечения рака молочной железы //Врач. – 2012; 11: 2-4.
2. Секундова М.А., Борисов В.И., Сдвижков А.М. Результаты комплексною лечения трижды ^егатив^ого рака молочной железы. Оиухоли репродуктивной системы // Практ. онколо­гия. – 2014; 11(4): 58-62.
3. Юлянди^ С.А., Фролова М.А., Сте^и^а М.Б., Тюлянди^ С.А. Тройной ^егатив^ый рак молочной железы // Практ. онко­логия. – 2010; 11(4): 247-252.
4. Burstein M. D., Tsimelzon A., Poage G. M. et al. Comprehensive Genonmic Analysis Identifies Novel Subtypes and Targets of Triple­Negative Breast Cancer. 2015; Clin Cancer Res. Vol. 21 Issue 7: 1688-1698.
5. DeSantis C., Chunchieh L., Mariotto A. B. et al. Cancer Treatment and Survivorship Statistic. // J Clin Oncol. 2014.
6. Emad A. Rakha, Jorge S. Reis-Filho et al. Basal-Like Breast Cancer: A Critical Review // J.Clin.Oncol. – 2008; 26: 2568-2581.
7. Mariotto A. B., Yabroff K. R., Shao Y. et al. Projections of the cost of cancer care in United States: 2010-2020. J Nati Cancer Inst 2011; 103(2): 117-28.
8. Milikan R. C., Newman B., Tse C-K. et al. Epidemiology of basal- like breast cancer. BCRT 2008.
9. Prat A., Perou C. M. et al. Molecular stratification of triple negative breast cancer. MolOncol. 2010.
10. Chavez K. J., GarimellaS. V., Lipkowitz S. Triple negative breast cancer cell lines: one tool in search for better treatment of triple negative breast cancer. Breast Dis. 2010; 32 (1-2): 35-48.
11. Cheang M. C., Voduc D., Bajdik C. et al. Basal-like breast cancer degined by five biomarkers has superior prognostic value than triple-negative phenotype. // Clin Cancer Res. 2008; 14: 1368­1376.
12. Liedtke C., Mazouni C., Hess K. R. et al. Response to neoajuvant therapy and long-term survival in patients with triple negative breast cancer. // J Clin Oncol. 2008; 26(19).
13. Lehmann B. D., Bauer J. A., Chen X. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. // J Clin Invest. 2011; 121: 2750-2767.
14. Herschkowitz J. I., Simin K., Weigman V. J. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007; 8: R76.